1. What is it?
Afamelanotide is a synthetic peptide similar to the natural hormone that stimulates skin pigment production. Melanotan I is a historical name for this molecule; Scenesse is the name of a specific medicine supplied as an implant. Melanotan II is a different substance with a different body of research. This distinction is fundamental: evidence about Scenesse does not establish the safety or effectiveness of every product broadly described as melanotan, even when its advertising cites medical studies. [129] [130]
2. Why do people turn to it?
The approved European indication concerns adults with EPP, erythropoietic protoporphyria. In this rare condition, light exposure can cause severe pain and restrict ordinary outdoor activities. Treatment aims to reduce these reactions and improve daily life, not produce a holiday tan. Benefits and risks in EPP therefore differ greatly from those in a healthy person wanting a different skin colour. [129] [131]
3. How does it work?
Afamelanotide mainly stimulates the MC1R receptor in pigment-producing cells. This encourages production of eumelanin, the dark form of melanin. The pigment absorbs some light and helps protect cells from its effects. Skin darkening may accompany this process. However, that visible effect does not mean that the skin has become resistant to all damage. The medicine's information recommends continuing the light and sun protection measures used previously. [130]
4. What do studies actually show?
A 2015 publication described two randomised trials in patients with EPP. They showed longer periods in sunlight without pain and improved quality of life. There is also an observational study of 115 people treated at two centres, with follow-up extending to eight years. It adds knowledge about longer-term use. Both types of data, however, concern people with EPP and specific implants, rather than cosmetic tanning. [131] [132]
5. What do we still not know?
EPP is rare, making it difficult to recruit very large study groups. In long-term follow-up, some people discontinued treatment for various reasons, which also affects interpretation. The ability to spend time in daylight also depends on weather, habits and fear of pain. Results should therefore not be reduced to a single promise for every patient. The studies also do not show that afamelanotide repairs the disease's genetic cause or removes the need for ongoing care. [131] [132]
6. What are the risks?
Reported side effects include nausea, headache and reactions at the implant site. Hypersensitivity reactions are also possible. Afamelanotide can darken existing pigmented skin lesions, so the product information calls for regular skin examinations. Darker skin is not a reason to increase UV exposure. Liver and kidney health also matter when assessing suitability for treatment. These are parts of a specialist assessment that cannot be replaced by knowing how the peptide works. [130]
7. Is it an approved medicine?
Scenesse received marketing authorisation in the European Union on 22 December 2014. Its indication is prevention of phototoxic reactions in adults with EPP. Authorisation was granted under exceptional circumstances because the rarity of the condition limited the ability to gather complete data. The medicine remains under monitoring, and treatment is provided by appropriate specialist centres. This status does not cover an unverified vial or nasal product marketed under a similar name to change skin colour. [129] [130]
8. What is new in research?
The EMA page and product information were updated on 7 October 2026. The currently confirmed indication remains adults with EPP. A recent document date alone does not mean authorisation for tanning or approval for a new patient group. Further data on the safety and benefits of actual EPP treatment remain most important to readers. The older 2015 studies provide a foundation for understanding, but are not presented here as new developments. [129] [132]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- Scenesse
Current EMA documentation; page updated 7 October 2026; indication, authorisation status, mechanism and monitoring information reviewed. Accessed: 3 November 2026.
- Afamelanotide for Erythropoietic Protoporphyria
Two randomised trials in patients with EPP; 2 July 2015; PubMed abstract reviewed · DOI: 10.1056/NEJMoa1411481. Accessed: 3 November 2026.
- Scenesse, INN-afamelanotide
EMA product information updated 7 October 2026; indication and sections on contraindications, warnings and side effects reviewed. Accessed: 3 November 2026.
- Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria
Long-term human follow-up; 2015; PubMed metadata and publisher's abstract read, not the full text · DOI: 10.1111/bjd.13598. Accessed: 03.11.2026.